{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:48:51Z","timestamp":1789019331865,"version":"build-2803163510"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T00:00:00Z","timestamp":1679529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T00:00:00Z","timestamp":1679529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Women's Health"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Every year, large number of women are suffering from cervical cancer. Particularly women living with HIV are at high-risk of being suffered with it. Early testing of high-risk human papillomavirus infection can significantly reduce the incidence of cervical cancer. However, lack of early and regular testing has been identified as one of the major problems among risky populations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Institutional-based cross-sectional study design was conducted among women living with HIV in Shashemene town public health facilities with a total sample size of 406 from February 1\u2013March 30, 2022. Systematic random sampling technique was employed to select the study subjects. A structured questionnaire and checklist was used to collect data. The collected data were cleaned, coded, and entered into Epi-info version 7.2.5 and exported to statistical package for social science version 24 for analysis. Finally, bi-variable and multivariable logistic regression analyses were performed to identify determinants of high-risk human papillomavirus. Odds ratio with 95% confidence interval was used to test association between exposure and outcome under study and\n                      <jats:italic>p<\/jats:italic>\n                      -value\u2009&lt;\u20090.05 was considered significant.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The prevalence of high-risk HPV infections among study participant was 173(35.2%) with 95% CI (30.5%-40.1%). Prevalence of high-risk HPV type 16, 18 and other high-risk HPV types were 62(15.3%), 23(5.7%) and 58(14.3%), respectively. Having history of sexually transmitted infections [AOR\u2009=\u20093.120; 95% CI (1.977\u20134.923)], Endline CD4 count\u2009&lt;\u2009200 cells\/mm3 [AOR\u2009=\u20093.072; 95% CI(1.009\u20139.350)], Endline HIV viral-load\u2009\u2265\u200950 copies\/ml [AOR\u2009=\u20093.446; 95% CI(1.368\u20138.683)] and more than one-lifetime sexual partner [AOR\u2009=\u20092.112; 95% CI(1.297\u20133.441)] were significantly associated with high-risk HPV infections.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>More than one third of women living with HIV had high-risk HPV. Having history of STI, low CD4 count, high viral load and multiple sexual partners were associated with high risk HPV. HIV positive women with these risk factors should be given special consideration in clinical and public health intervention.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12905-023-02279-2","type":"journal-article","created":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T17:24:05Z","timestamp":1679592245000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Prevalence of high-risk human papillomavirus infections and associated factors among women living with HIV in Shashemene town public health facilities, Southern Ethiopia"],"prefix":"10.1186","volume":"23","author":[{"given":"Tariku","family":"Megersa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sisay","family":"Dango","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kebede","family":"Kumsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kebebew","family":"Lemma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bikila","family":"Lencha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,23]]},"reference":[{"key":"2279_CR1","unstructured":"WHO, Human papillomavirus (HPV) and cervical cancer. 2020."},{"key":"2279_CR2","unstructured":"Gynecologic Oncology, Williams Gynecology, cervical cancer. Access Medicine, 2008. chapter 30."},{"issue":"2","key":"2279_CR3","doi-asserted-by":"publisher","first-page":"e191","DOI":"10.1016\/S2214-109X(19)30482-6","volume":"8","author":"M Arbyn","year":"2020","unstructured":"Arbyn M, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Global Health. 2020;8(2):e191\u2013203.","journal-title":"Lancet Global Health"},{"issue":"1","key":"2279_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/CMR.16.1.1-17.2003","volume":"16","author":"EM Burd","year":"2003","unstructured":"Burd EM. Human Papillomavirus and Cervical Cancer. Clin Microbiol Rev. 2003;16(1):1\u201317.","journal-title":"Clin Microbiol Rev"},{"key":"2279_CR5","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.bpobgyn.2017.08.006","volume":"47","author":"B Serrano","year":"2018","unstructured":"Serrano B, et al. Epidemiology and burden of HPV-related disease. Best Pract Res Clin Obstet Gynaecol. 2018;47:14\u201326.","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"2279_CR6","unstructured":"Samanta M. Pfeife, Obstetrics and Gynecology, 6th Edition. NMS, 2008. Chapter 39: p. 427."},{"key":"2279_CR7","doi-asserted-by":"crossref","unstructured":"Sung, H., J. Ferlay, and R.L. Siegel, Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. 2021. 71(3): p. 209\u2013249.","DOI":"10.3322\/caac.21660"},{"issue":"5","key":"2279_CR8","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.4161\/hv.27925","volume":"10","author":"L Toft","year":"2014","unstructured":"Toft L, et al. Comparison of the immunogenicity of Cervarix\u00ae and Gardasil\u00ae human papillomavirus vaccines for oncogenic non-vaccine serotypes HPV-31, HPV-33, and HPV-45 in HIV-infected adults. Human Vaccin Immunother. 2014;10(5):1147\u201354.","journal-title":"Human Vaccin Immunother"},{"issue":"48","key":"2279_CR9","doi-asserted-by":"publisher","first-page":"5745","DOI":"10.1016\/j.vaccine.2013.09.032","volume":"31","author":"L Denny","year":"2013","unstructured":"Denny L, et al. Safety and immunogenicity of the HPV-16\/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study. Vaccine. 2013;31(48):5745\u201353.","journal-title":"Vaccine"},{"key":"2279_CR10","unstructured":"Organization, W.H., Global strategy to accelerate the elimination of cervical cancer as a public health problem. 2020."},{"key":"2279_CR11","unstructured":"FMOH, Guilines for cervical cancer prevention and control in Ethiopia. 2021: p. 21\u201325."},{"key":"2279_CR12","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2147\/IJWH.S153003","volume":"10","author":"DY Mohammed","year":"2018","unstructured":"Mohammed DY, et al. Increased proportions of HIV-infected women met cervical cancer screening guideline in 2016. Int J Women\u2019s Health. 2018;10:83.","journal-title":"Int J Women's Health"},{"issue":"3","key":"2279_CR13","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"2279_CR14","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424.","journal-title":"CA Cancer J Clin"},{"issue":"10224","key":"2279_CR15","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/S0140-6736(20)30068-4","volume":"395","author":"M Brisson","year":"2020","unstructured":"Brisson M, et al. Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet. 2020;395(10224):575\u201390.","journal-title":"Lancet"},{"key":"2279_CR16","unstructured":"Bruni L, A.G., et al., Human Papilomavirus and related disease report, www.hpvcentre.net. HPV Information center, 2021."},{"issue":"2","key":"2279_CR17","doi-asserted-by":"publisher","first-page":"e161","DOI":"10.1016\/S2214-109X(20)30459-9","volume":"9","author":"D Stelzle","year":"2021","unstructured":"Stelzle D, et al. Estimates of the global burden of cervical cancer associated with HIV. Lancet Global Health. 2021;9(2):e161\u20139.","journal-title":"Lancet Global Health"},{"issue":"1","key":"2279_CR18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12985-017-0913-3","volume":"15","author":"MF Teixeira","year":"2018","unstructured":"Teixeira MF, et al. High risk human papillomavirus prevalence and genotype distribution among women infected with HIV in Manaus. Amazonas Virol J. 2018;15(1):1\u201312.","journal-title":"Amazonas Virol J"},{"issue":"1","key":"2279_CR19","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1093\/infdis\/jiaa065","volume":"222","author":"G Murenzi","year":"2020","unstructured":"Murenzi G, et al. Twelve-Year Trend in the Prevalence of High-Risk Human Papillomavirus Infection Among Rwandan Women Living With HIV. J Infect Dis. 2020;222(1):74\u201381.","journal-title":"J Infect Dis"},{"issue":"1","key":"2279_CR20","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.ygyno.2018.08.004","volume":"151","author":"LLS Rodrigues","year":"2018","unstructured":"Rodrigues LLS, et al. Cervico-vaginal self-collection in HIV-infected and uninfected women from Tapaj\u00f3s region, Amazon, Brazil: High acceptability, hrHPV diversity and risk factors. Gynecol Oncol. 2018;151(1):102\u201310.","journal-title":"Gynecol Oncol"},{"issue":"12","key":"2279_CR21","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1002\/jmv.24906","volume":"89","author":"AE Miranda","year":"2017","unstructured":"Miranda AE, et al. High-risk papillomavirus infection among women living with human Immunodeficiency virus: Brazilian multicentric study. J Med Virol. 2017;89(12):2217\u201323.","journal-title":"J Med Virol"},{"key":"2279_CR22","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13027-015-0040-y","volume":"10","author":"E Belglaiaa","year":"2015","unstructured":"Belglaiaa E, et al. Human papillomavirus genotypes among women with or without HIV infection: an epidemiological study of Moroccan women from the Souss area. Infect Agents Cancer. 2015;10:44.","journal-title":"Infect Agents Cancer"},{"key":"2279_CR23","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.ijid.2020.02.051","volume":"95","author":"O Taku","year":"2020","unstructured":"Taku O, et al. Human papillomavirus prevalence and risk factors among HIV-negative and HIV-positive women residing in rural Eastern Cape. South Africa Int J Infect Dis. 2020;95:176\u201382.","journal-title":"South Africa Int J Infect Dis"},{"issue":"3","key":"2279_CR24","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1097\/LGT.0b013e31818fb40d","volume":"13","author":"A Peedicayil","year":"2009","unstructured":"Peedicayil A, et al. Prevalence and risk factors for human papillomavirus and cervical intraepithelial neoplasia among HIV-positive women at a tertiary level hospital in India. J Lower Genital Tract Dis. 2009;13(3):159\u201364.","journal-title":"J Lower Genital Tract Dis"},{"issue":"2","key":"2279_CR25","first-page":"185","volume":"160","author":"C Hankins","year":"1999","unstructured":"Hankins C, et al. Prevalence of risk factors associated with human papillomavirus infection in women living with HIV. Canadian Women\u2019s HIV Study Group CMAJ. 1999;160(2):185\u201391.","journal-title":"Canadian Women's HIV Study Group CMAJ"},{"key":"2279_CR26","doi-asserted-by":"crossref","unstructured":"Caicedo-Mart\u00ednez, M., et al., High-risk human papillomavirus infection among women living with HIV in Latin America and the Caribbean: A systematic review and meta-analysis. Int J STD AIDS, 2021: p. 09564624211037498.","DOI":"10.1177\/09564624211037498"},{"issue":"9","key":"2279_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0221334","volume":"14","author":"S Abel","year":"2019","unstructured":"Abel S, et al. High prevalence of human papillomavirus infection in HIV-infected women living in French Antilles and French Guiana. PLoS ONE. 2019;14(9): e0221334.","journal-title":"PLoS ONE"},{"issue":"1","key":"2279_CR28","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1001\/jama.2018.7464","volume":"320","author":"GS Ogilvie","year":"2018","unstructured":"Ogilvie GS, et al. Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 Months: The HPV FOCAL Randomized Clinical Trial. JAMA. 2018;320(1):43\u201352.","journal-title":"JAMA"},{"issue":"6","key":"2279_CR29","doi-asserted-by":"publisher","first-page":"281","DOI":"10.5306\/wjco.v6.i6.281","volume":"6","author":"R Catarino","year":"2015","unstructured":"Catarino R, et al. Cervical cancer screening in developing countries at a crossroad: Emerging technologies and policy choices. World J Clin Oncol. 2015;6(6):281\u201390.","journal-title":"World J Clin Oncol"},{"key":"2279_CR30","unstructured":"town, S., Shashemene town estimated population statistics 2021."},{"key":"2279_CR31","unstructured":"National cancer institute, HPV and cancer. 2021."},{"issue":"10","key":"2279_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0163965","volume":"11","author":"S Menon","year":"2016","unstructured":"Menon S, et al. Epidemiology of HPV genotypes among HIV positive women in Kenya: a systematic review and meta-analysis. PLoS ONE. 2016;11(10): e0163965.","journal-title":"PLoS ONE"},{"key":"2279_CR33","doi-asserted-by":"publisher","first-page":"104445","DOI":"10.1016\/j.jcv.2020.104445","volume":"128","author":"A Adedimeji","year":"2020","unstructured":"Adedimeji A, et al. Cervical human papillomavirus DNA detection in women living with HIV and HIV-uninfected women living in Limbe. Cameroon J Clin Virol. 2020;128:104445\u2013104445.","journal-title":"Cameroon J Clin Virol"},{"issue":"2","key":"2279_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0229086","volume":"15","author":"PE Castle","year":"2020","unstructured":"Castle PE, et al. High-risk human papillomavirus prevalence in self-collected cervicovaginal specimens from human immunodeficiency virus (HIV)-negative women and women living with HIV living in Botswana. PLoS ONE. 2020;15(2): e0229086.","journal-title":"PLoS ONE"},{"issue":"1","key":"2279_CR35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0085429","volume":"9","author":"DN Dames","year":"2014","unstructured":"Dames DN, et al. High-risk cervical human papillomavirus infections among human immunodeficiency virus-positive women in the Bahamas. PLoS ONE. 2014;9(1): e85429.","journal-title":"PLoS ONE"},{"key":"2279_CR36","doi-asserted-by":"crossref","unstructured":"Silva, L.d., et al., High-risk human papillomavirus and cervical lesions among women living with HIV\/AIDS in Brazilian Amazon, Brazil. Braz J Infectious Dis, 2015. 19: p. 557\u2013562.","DOI":"10.1016\/j.bjid.2015.07.001"},{"issue":"1","key":"2279_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-016-2881-1","volume":"16","author":"K Thorsteinsson","year":"2016","unstructured":"Thorsteinsson K, et al. Prevalence and distribution of cervical high-risk human papillomavirus and cytological abnormalities in women living with HIV in Denmark\u2013the SHADE. BMC Cancer. 2016;16(1):1\u201313.","journal-title":"BMC Cancer"}],"container-title":["BMC Women's Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-023-02279-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12905-023-02279-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-023-02279-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T17:24:42Z","timestamp":1679592282000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcwomenshealth.biomedcentral.com\/articles\/10.1186\/s12905-023-02279-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,23]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2279"],"URL":"https:\/\/doi.org\/10.1186\/s12905-023-02279-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2099833\/v1","asserted-by":"object"}]},"ISSN":["1472-6874"],"issn-type":[{"value":"1472-6874","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,23]]},"assertion":[{"value":"24 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was carried out after obtaining ethical clearance from Madda Walabu University Shashemene campus (MWUSHC\/1588\/14), the ethical review committee, and the supportive letter was submitted to health facility managers. An official letter was given to the focal person ART and MCH unit. Respondents were informed about the objective and purpose of the study and written informed consent were obtained from each respondent. Clear information was given about the purpose and procedure of the study, the importance of participation, and the right to withdraw at any time if they want. Privacy and confidentiality of the information given for each respondent kept properly. During the data collection procedure COVID-19 pandemic prevention methods were applied by data collectors following scientific guidelines. All methods were carried out in accordance with relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"NA","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent of publication"}},{"value":"There is no competing interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"125"}}